Newsfeeds - Spark Newswire

4 minute read

The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation

By Vandana Singh

Today, 1:00 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABEO

3 minute read

Earnings Scheduled For May 17, 2022

By Benzinga Insights

Today, 1:00 PM

Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter.

AER

1 minute read

Earnings

Earnings Preview: ObsEva

By Benzinga Insights

Today, 1:00 PM

ObsEva (NASDAQ:OBSV) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that ObsEva will report an earnings per share (EPS) of $-0.20.

OBSV

2 minute read

News

ObsEva Announces Confirmation Of Positive CHMP Opinion For Linzagolix, An Oral GnRH Antagonist, For The Treatment of Uterine Fibroids

By Benzinga Newsdesk

Today, 1:00 PM

ObsEva SA (NASDAQ:OBSV, SIX: OBSN)), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Committee for Medicinal Products for Human Use (CHMP) of

OBSV

1 minute read

HC Wainwright & Co. Maintains Buy on ObsEva, Lowers Price Target to $11

By Benzinga Newsdesk

Today, 1:00 PM

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ObsEva (NASDAQ:OBSV) with a Buy and lowers the price target from $15 to $11.

OBSV

1 minute read

ObsEva Unveils Additional Efficacy Results for Linzagolix In Endometriosis-Associated Pain

By Vandana Singh

Today, 1:00 PM

ObsEva SA (NASDAQ:OBSV) has announced additional efficacy results from the Phase 3 EDELWEISS 3 trial of linzagolix for moderate-to-severe endometriosis-associated pain…

OBSV

1 minute read

ObsEva: Q4 Earnings Insights

By Benzinga Insights

Today, 1:00 PM

ObsEva (NASDAQ:OBSV) reported its Q4 earnings results on Thursday, March 10, 2022 at 01:00 AM. Here's what investors need to know about the announcement.

OBSV

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 1:00 PM

On Monday, 524 stocks hit new 52-week lows.

AAL

1 minute read

ObsEva Expects Delay In Linzagolix Application Submission In Europe For Uterine Fibroids

By Vandana Singh

Today, 1:00 PM

ObsEva SA (NASDAQ: OBSV) said that based on ongoing communications with the European Medicines Agency (EMA), it expects further questions on the linzagolix application, thereby

OBSV

2 minute read

16 Stocks Moving in Tuesday’s Pre-Market Session

By Lisa Levin

Today, 1:00 PM

Gainers

CIAN